We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Sarepta Therapeutics

News List

Sarepta to Seek FDA Approval for Second DMD Treatment biospace
March 13, 2018
Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) is planning on seeking approval of a second treatment for Duchenne muscular dystrophy (DMD).
Deals this week: Fidson Healthcare, Sarepta Therapeutics, North China Pharmaceutical pharmaceutical-technology
July 31, 2017
Nigerian pharmaceutical company Fidson Healthcare plans to raise NGN6bn ($18.65m) through a rights offering of shares.
Sarepta Therapeutics Opens Research and Mfg. Center contractpharma
June 28, 2017
60,000-sq.-ft. Andover facility significantly enhances its research and manufacturing capabilities